The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

Merck (MRK) will be in focus as company beats revenue forecasts despite in line earnings amid strong Keytruda sales in Q3 ...

Anyone crafting a bull case for the pharmaceutical giant Merck (NYSE: MRK) should include Keytruda as the ... The Motley Fool Stock Advisor analyst team just identified what they believe are ...

Merck stock fell early Monday after a rival pharmaceutical company said its cancer drug beat Merck’s Keytruda in a ...

IO Biotech (IOBT) announced data from the NSCLC cohort in the company’s Phase 2 basket trial of IO102-IO103, the company’s lead investigational candidate, given in combination with Merck’s anti-PD-1 ...

Merck (MRK) is set to announce Q3 earnings on October 31st. Analysts expect a profit of $1.57 per share on revenue of $16.51B ...

Investors in Merck don't seem pleased with a competitor cancer-treatment candidate outperforming Keytruda. Summit Therapeutics says its monotherapy ivonescimab outperformed pembrolizumab ...

Charlie CY Yang has given his Buy rating due to a combination of factors, including the strong performance and potential of Merck’s key products, particularly Keytruda and Gardasil. The growth ...